Search

Levomilnacipran

[L47956] While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use.[L48011] … Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.

Citrus bioflavonoids

Infigratinib

cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test. … [A198963] Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR receptor subtypes.

Astemizole

Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. … It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.

Pancrelipase protease

[L2509] The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion. … Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands.

Opium

[A32175] Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. … in the category of isoquinolines.

Cilnidipine

Compared with other calcium antagonists, cilnidipine can act on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to most of the calcium … Cilnidipine is a dihydropyridine calcium antagonist. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995.

Sepiapterin

Sepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria. … [L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria.

Dorocubicel

[L54106] Dorocubicel, as a component of Zemcelpro, was granted conditional marketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation … following myeloablative conditioning in adult patients for whom a suitable donor is not available.

Norepinephrine

It is also found in plants and is used pharmacologically as a sympathomimetic. … Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter.